(S)-C33|C33(S)

Cas No.:	2066488-39-7
Chemical Name:	(S)-6-((1-(4-chlorophenyl)ethyl)amino)-1-cyclopentyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Synonyms:	C33(S)
SMILES:	C(N[C@@H](C1=CC=C(Cl)C=C1)C)1NC(=O)C2C=NN(C3CCCC3)C=2N=1
Formula:	C₁₈H₂₀ClN₅O
M.Wt:	357.837302207947
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A novel potent, selective PDE9A inhibitor with IC50 of 11 nM, >45-fold selectivity over other PDE isoforms; shows better selectivity than (R)-C33 against PDE5.

Cat. No.	Product name	Field of application
DC47387	PDE4-IN-3	PDE4-IN-3 is a novel and orally active PDE4 inhibitor with potent inhibitory affinity (IC50 = 4.2 nM).
DC47386	N-Desmethyl Sildenafil	N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor.
DC47223	Ro 20-1724	Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase (PDE4/PDE IV) with a Ki of 1930 nM. Neuroprotective effect.
DC47201	Irsenontrine	Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE 9) inhibitor. Irsenontrine can be used for the research of neurological diseases.
DC47087	Orismilast	Orismilast (LEO-32731) is a PDE4 inhibitor used for the research of inflammatory diseases.
DC46874	Carbazeran citrate	Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease.
DC46873	Senazodan hydrochloride	Senazodan (MCI 154) (hydrochloride), as a Ca2+ sensitiser, shows inhibition effect on PDE III.
DC46435	PF-8380 hydrochloride	PF-8380 hydrochloride is a potent autotaxin inhibitor with an IC50 of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.
DC46402	Tovinontrine	Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively.
DC46253	LASSBio-1632	LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion.